首页> 外文OA文献 >Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

【2h】

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

机译：从促进蛋白酶抑制剂的基于促进蛋白酶抑制剂的方案在病毒学抑制患者的高血管内风险或年龄≥50岁的患者中，直接与延迟切换到患者中的患者：最终96周的Neat022研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

相似文献

外文文献
中文文献
专利

1. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age = 50 Years: Final 96-Week Results of the NEAT022 Study [J] . Gatell Jose M., Assoumou Lambert, Stellbrink Hans-Juergen, Clinical infectious diseases . 2019,第4期

机译：从促进的蛋白酶抑制剂的基于促进蛋白酶抑制剂的方案的直接与病毒学抑制的患者在病变抑制的患者中的方案，高血管内风险或年龄较高的患者。= 50年：Neat022研究的最终96周的结果
2. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk [J] . Gatell Jose M., Assoumou Lambert, Moyle Graeme, AIDS . 2017,第18期

机译：从Ritonavir促进的蛋白酶抑制剂切换到基于DoluteGravir的方案，用于维持高血管内风险高患者的HIV病毒抑制
3. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study [J] . JAIDS: Journal of acquired immune deficiency syndromes . 2020,第3期

机译：在病毒学抑制的病毒抑制患者中转换为Darunavir / CObicistat的有效性，接受Ritonavir-Boosted Protease抑制剂的基于植物的方案：“商店”研究
4. Virological Outcome of Tenofovir plus Abacavir-based Regimens in Previously HIV Suppressed Patients (RECOVER STUDY) [C] . S. Moreno, M.J. Perez Elias, J.A. Terron International AIDS Conference . 2004

机译：以前艾滋病病毒抑制患者在替诺福韦加上基于Abacavir的病毒学结果（恢复研究）
5. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk [O] . José M. Gatell, Lambert Assoumou, Graeme Moyle, -1

机译：从利托那韦增强蛋白酶抑制剂转换为基于多洛格韦的方案以维持高心血管风险患者的HIV病毒抑制
6. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk [O] . Gatell, Jose, Guaraldi, Giovanni Paolo, Masia, Mar M., 2017

机译：从利托那韦增强蛋白酶抑制剂转换为基于多洛格韦的方案，以维持高心血管风险患者的HIV病毒抑制

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

著录项

引文网络

相似文献

相关主题

期刊订阅